Publications
A Multi Gene Targeting Approach to Treating Liver Diseases with Metadichol®
Journal of Cytokine Biology, 1-2019 Metadichol® is a nanoemulsion of long-chain alcohols derived from food sources. It functions as an inverse agonist of the Vitamin D Receptor (VDR) and demonstrates a multi-gene targeting approach by modulating key inflammatory and metabolic pathways involved in liver disease, Metadichol® inhibits TNF-alpha, ICAM1, CCL2 (MCP-1), and PAI1, all of which are central to liver inflammation, fibrosis, and progression to cirrhosis and hepatocellular carcinoma (HCC). By binding to VDR, Metadichol® promotes a Th2 immune response and suppresses the Th17 pathway, reducing inflammation. It also downregulates IFN-γ, a cytokine linked to liver disease severity.
A Systems-Level Paradigm: Metadichol® Coordinated Regulation of LINE1, HMGB1, and USAG1 for Immune Enhancement.
1-20-26 Metadichol® orchestrates a systems-level response integrating innate immunity (LINE1), inflammatory amplification (HMGB1), and tumor suppression (USAG1) within a comprehensive protective framework involving nuclear receptors, sirtuins, FOXO factors, Klotho, vitamin C-TET enzymes, and circadian regulators. This paradigm shift from immunosuppression to controlled immuno-stimulation opens new therapeutic avenues for cancer and immune enhancement.
Beyond Rapamycin: Metadichol® Represents a New Class of Multi-Target mTOR Modulators
European Society of Medicine, Medical Research Archives 9-30-2025 Metadichol® represents a new class of mTOR modulators with unprecedented potency and multi-target activity, significantly differentiating it from conventional inhibitors like rapamycin. The nanoemulsion of long-chain alcohols (primarily C28) modulates the mechanistic target of rapamycin (mTOR) signaling pathway—a central regulator of cellular growth, metabolism, and survival.
BioRxiv Cold Spring Harbor Lab
Metadichol Expression of Toll Like Receptors in Cancer Cell Lines
BioRxiv Cold Spring Harbor Lab
Metadichol CD14 Glycoprotein Expression in Stem Cells and Fibroblasts
Biology and Medicine
Metadichol - Vitamin C and GULO Gene Expression
Biology and Medicine
Metadichol - A Novel Inverse Agonist of Thyroid Recepto
Clinical and Biomedical Research
Metadichol - Expresses All 49 Nuclear Receptors
European Society of Medicine
Metadichol Expression of Toll Receptor Family in Peripheral Blood Mononuclear Cells
European Society of Medicine
Metadichol Expression of Sirtuin 1-7 In Somatic and Cancer Cells
European Society of Medicine
Metadichol Expression of Circadian Clock Transcription Factors in Human Fibroblasts
European Society of Medicine
Expression of Yamanaka Reprogramming Factors in Cardiac, Fibroblast, and Cancer Cell Lines
European Society of Medicine
Metadichol-Induced Differentiation of Pancreatic Ductal Cells (PANC-1) into Insulin-Producing Cells
Fortune Journals Cardiology & Cardiovascular Therapy
Metadichol Fibroblasts and Embryonic Stem Cells Regulates Key Cardiac Progenitors
Fortune Journals of Health Sciences
Metadichol - A Novel Agonist of the Anti-Aging Klotho Gene in Cancer Cell Lines
Improving Longevity with Metadichol ® by Inhibiting the BCAT1 Gene
Journal of Aging Science, 3-2017 Metadichol® functions as an inverse agonist on nuclear vitamin D receptors (VDR), influencing immune function and multiple biological processes. Research indicates that Metadichol® inhibits the BCAT1 gene, which encodes branched-chain amino acid transferase 1—a key enzyme in the metabolism of branched-chain amino acids (BCAAs).
In vitro Inhibition of Zika Virus by Metadichol®, A Novel Nano Emulsion Lipid
Journal of Immunological Techniques in Infectious Diseases, 11-2016 The antiviral effect of Metadichol® is believed to stem from its interaction with the vitamin D receptor (VDR) on host cell membranes. As Metadichol® binds to VDR, it may competitively displace virus particles that exploit this receptor for cellular entry. This mechanism is particularly relevant for enveloped viruses like Zika, which possess a lipid membrane crucial for infectivity.
Inhibition of Dengue and other enveloped viruses by Metadichol®, a novel Nano emulsion Lipid
Journal of the Science of Healing Outcomes, 4-2016 Metadichol® has demonstrated significant in vitro inhibition of enveloped viruses through mechanisms involving competitive binding to the vitamin D receptor (VDR) on host cell membranes, thereby disrupting viral entry and reactivating innate immune responses.
Inhibition of Viruses by Metadichol®: A Novel Nano Emulsion Lipid
iMedPub Journals, Pediatric Infectious Diseases 1-2017 Metadichol®, a novel nanoemulsion composed of long-chain lipid alcohols (policosanols), has demonstrated broad-spectrum antiviral activity in vitro against multiple pathogenic viruses relevant to pediatric infectious diseases. Studies have shown its efficacy against Dengue, Ebola, Marburg, Influenza A (H1N1), Chikungunya, Respiratory Syncytial Virus (RSV), Zika, SARS-CoV, and SARS-CoV-2, among others. The compound works by binding to the vitamin D receptor (VDR) as an inverse agonist or protean agonist, thereby reactivating innate immune function that viruses like Epstein-Barr often suppress. This mechanism helps restore the body's natural defense system.
International Conference: Scientific Milestones in Understanding and Preventing Flu
Metadichol - A Novel ICAM-1 Inhibitor
Journal of Aging Science
Improving Longevity by Inhibiting BCAT1 Gene
Journal of Arthritis
Rheumatoid Arthritis and Osteoporosis: A Case Study
Journal of Bioinformatics and Systems Biology
Metadichol - Expression of Neuronal Transcription Factors
Journal of Cancer Science and Therapy
A Novel Inverse Agonist of AHR and NRF2 Inhibitor
Journal of Cardiology & Cardiovascular Therapy
Systolic and Diastolic BP Control in Metabolic Syndrome
Journal of Clinical and Experimental Dermatology
Metadichol and Healthy Skin
Journal of Clinical and Experimental Dermatology
A Novel ROR Gamma Inverse Agonist and Psoriasis
Journal of Cytokine Biology
Metadichol - Liver Diseases
Journal of Diabetes Complications
Metadichol - A Novel Nano Lipid GPR 120 Agonist
Journal of Diabetes & Metabolism
Metadichol - A Novel Nano Lipid and Diabetes
Journal of Immunological Techniques in Infectious Diseases
Metadichol - In Vitro Inhibition of Zika Virus
Journal of Infectious Diseases and Therapy
Metadichol and MRSA: A Case Report
Journal of Stem Cell Research and Therapy
Metadichol - A Novel Telomerase Activator
Journal of Stem Cell Research and Therapy
IRS Proteins and GLUT4 Expression
Journal of Stem Cell Research and Therapy
CD33 Expression in Umbilical Cord Cells
Journal of Stem Cell Research and Therapy
CD34 Expression in Umbilical Cord Cells
Journal of Stem Cell Research and Therapy
Metadichol - Red Cell Distribution Width (RDW) in Chronic Kidney Disease
Journal of Stem Cell Research & Therapy
Metadichol - A Novel Sialidase Inhibitor
Journal of The Science of Healing Outcomes
Metadichol - Inhibition of Dengue and Other Enveloped Viruses
Journal of The Science of Healing Outcomes
Type I Diabetes: A Case Report
Metadichol®, a modulator that controls expression of Toll Like Receptors in Cancer Cell Lines
bioRxiv, 7-20-24 Metadichol® is investigated for its ability to modulate the expression of Toll-like receptors (TLRs) in cancer cell lines.
Metadichol® A Nano Lipid Emulsion that Expresses All 48/49 Nuclear Receptors in Stem and Somatic Cells
Fortune Journals, 10-25-23 Human nuclear receptors (NRs) involve 49 ligand-dependent transcription factors that are important for regulating the cell cycle and processes. Metadichol® is a nanoemulsion composed of long-chain lipid alcohols, studied for its ability to activate all 49 known human nuclear receptors (NRs) in both stem and somatic cells
Metadichol®, a Natural Ligand for the Expression of Yamanaka Reprogramming Factors in Human Cardiac, Fibroblast, and Cancer Cell Lines
European Society of Medicine, Medical Research Archives, 7-1-24 Metadichol® is identified as a natural ligand that enhances the expression of Yamanaka reprogramming factors—Oct4, Sox2, Klf4, and c-Myc—in human somatic and cancer cell lines.
Metadichol - A Novel ICAM-1 Inhibitor
Inter'l Conference: Scientific Milestones in Understand and Preventing Flu Metadichol® functions as a potent ICAM-1 inhibitor, targeting a key receptor molecule used by the majority of viruses—including those causing the common cold, influenza, Dengue, Chikungunya, Ebola, and SARS-CoV-2—to enter host cells. Studies show that Metadichol® inhibits ICAM-1 expression, which plays a critical role in viral entry and immune cell infiltration, particularly in the lungs during severe infections like COVID-19. This inhibition helps reduce inflammation and tissue damage associated with cytokine storms. Its mechanism involves binding to the vitamin D receptor (VDR) (US Patent 9,006,292), leading to modulation of multiple inflammatory pathways, including suppression of TNF-alpha, CCL2, and NF-kB.
Metadichol®: A Novel Inverse Agonist of Aryl Hydrocarbon Receptor (AHR) and NRF2 Inhibitor
Journal of Cancer Science and Therapy, 1-2017 This paper shows how Metadichol® is an inverse agonist of the nuclear receptor AHR (Aryl Hydrocarbon receptor), an inhibitor of NRF2, and is a transcription factor that is ubiquitously expressed at low levels in all human organs and regulates a primary cellular defense mechanism to maintain cellular homeostasis. Inhibition of Nrf2 by Metadichol® holds promise as a therapeutic strategy in chemo resistant forms of cancer where there is a need to control AHR and NRF2 level.
Metadichol® A Novel Inverse Agonist of Thyroid Receptor and its Applications in Thyroid Diseases
Biology and Medicine, 4-2019 Metadichol® has been identified as an inverse agonist of multiple nuclear receptors, including THRA (Thyroid Receptor Alpha), THRB (Thyroid Receptor Beta), the Vitamin D receptor (VDR), Aryl Hydrocarbon Receptor (AHR), and RORC (RAR-related Orphan Receptor C). The nano-nutrient demonstrates potential in both hypothyroidism and hyperthyroidism, with case studies suggesting it can safely modulate thyroid hormone levels and reduce thyroid antibodies such as Thyroid Peroxidase Antibodies (TPOAb) and Thyroglobulin Antibodies (TGAb)—markers associated with autoimmune conditions like Hashimoto’s and Graves’ disease. It may also influence key pathways involved in thyroid hormone regulation, energy metabolism, and adipocyte differentiation.
Metadichol®, a novel nano lipid emulsion for the treatment of diabetes
Journal of Diabetes & Metabolism, 1-2017 Metadichol® is a nanoemulsion formulated from long-chain alcohols known as policosanols, has been reported to have benefits in supporting insulin sensitivity, blood glucose in normal range, and promoting optimal HbA1c levels. Key mechanisms of action include: Agonism of GPR120, a receptor linked to anti-inflammatory effects and improved insulin sensitivity. In vitro studies show its activity is comparable to GW9508, a well-established GPR120 agonist standard. Inverse agonism on Vitamin D Receptors (VDR), which are present in most cells and play a role in glucose homeostasis and immune modulation.
Metadichol® A Novel Nano Lipid; GPR 120 Agonist International Journal of Diabetes & its Complications
International Journal of Diabetes & its Complications, 5-2017 Metadichol® acts as an inverse agonist on Nuclear Vitamin D Receptor (VDR) and has been shown to modulate immune function and biological processes relevant to disease. Research published demonstrates it helping to modulate insulin levels, supporting healthy blood sugar, and promoting insulin sensitivity. A key finding is that Metadichol® also functions as an agonist of GPR120 (G protein-coupled receptor 120), a receptor that has emerged as a critical target for metabolic diseases such as obesity and insulin resistance. In vitro assays showed that Metadichol® activity at GPR120 is comparable to GW9508, the most widely used standard compound in GPR120 research. This dual mechanism—targeting both VDR and GPR120—suggests a multifaceted approach to improving glucose homeostasis and metabolic health.
Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro
BioMed Research International, PubMed, National Library of Medicine, 1-15-2022 Metadichol® is a nano lipid formulation composed of long-chain alcohols (C26, C28, and C30) that has demonstrated potent inhibitory effects against SARS-CoV-2 and multiple other pathological viruses in vitro.
Metadichol®, A Novel ROR Gamma Inverse Agonist and Its Applications in Psoriasis
Journal of Clinical & Experimental Dermatology Research, 11-2017 Metadichol® is proposed as a novel inverse agonist of RORγt (retinoic acid receptor-related orphan nuclear receptor gamma), Aryl Hydrocarbon Receptor (AHR), and Vitamin D Receptor (VDR). It is suggested to exert therapeutic effects in psoriasis by modulating key inflammatory pathways.